SEC Form 4 · accession 0001735276-18-000006
ALNYLAM PHARMACEUTICALS, INC. · ALNY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John K Clarke
Director
Period of report
May 31, 2018
Accepted (ET)
Jun 4, 2018 · 4:25 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001178670
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 31, 2018 | M | 15,000 | $27.28 | A | 23,891 | D | |
| Common StockF2 | May 31, 2018 | S | 2,758 | $99.38 | D | 21,133 | D | |
| Common StockF3 | May 31, 2018 | S | 10,042 | $100.33 | D | 11,091 | D | |
| Common StockF4 | May 31, 2018 | S | 2,100 | $101.37 | D | 8,991 | D | |
| Common Stock | May 31, 2018 | S | 100 | $101.97 | D | 8,891 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) | $27.28 | May 31, 2018 | M | 15,000 | D | Jun 3, 2009 | Jun 2, 2018 | Common Stock | 15,000 | 0 | D |
Explanation of responses
- F1All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 20, 2018.
- F2Sales prices ranged from $98.89 to $99.75.
- F3Sales prices ranged from $99.92 to $100.90.
- F4Sales prices ranged from $100.97 to $101.88.